Strategies to accelerate AAV chromatography process development

Kelley Kearns is the Director of Downstream Development at Repligen and has been instrumental in the development and production of bioprocess affinity chromatography resins, essential for the purification of biopharmaceuticals. With over 5 years in this role, he has shown an exceptional ability to solve complex technical challenges, ensuring the production of high-quality, life-saving medicines. Kelley Kearns is a highly accomplished professional with a successful track record in the development and commercialization of late-stage biopharmaceuticals. His expertise lies in bridging the gap between drug development and manufacturing, with a focus on process improvement and optimization.

In his previous roles, Kelley's contributions have been equally significant. As a Senior Scientist at Dynavax Technologies, he played a key role in supporting routine manufacturing, making critical technical decisions, troubleshooting, and implementing process improvements. At Bristol-Myers Squibb, Kelley managed laboratory studies for downstream process validation and supported commercial process improvements for late-stage biologics. As a Senior Engineer at Merck, Kelley displayed exemplary project management skills, overseeing the design and construction of multimillion-dollar facilities, resulting in enhanced production capabilities and substantial cost savings through process optimization.

Kelley holds a Doctor of Philosophy (Ph.D.) in Chemical Engineering from the University of Delaware, a Master's degree in Chemical Engineering from Rutgers University, and a Bachelor's degree in Chemical Engineering from The Cooper Union for the Advancement of Science and Art.